GlassScriptPhysician profile
Mitchell G Odom
NPI 1699909283
$4,068.87
in general payments reported to CMS, 2019-2025
20 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.75 · 2022: $498 · 2023: $596 · 2024: $1,680 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,387.30 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $636.06 | 2025 | Jornay Pm |
| Abbvie INC. | $343.88 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $268.66 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $171.93 | 2025 | |
| Alkermes, INC. | $165.84 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $133.88 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $124.22 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.96 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $112.41 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $111.90 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $99.15 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $89.59 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $65.14 | 2023-2025 | Rexulti |
| Corium, LLC | $52.23 | 2024 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $47.40 | 2024 | Relexxii |
| Tempus Ai, INC | $43.40 | 2024 | Tempus Pixel |
| Indivior INC. | $42.33 | 2023-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $35.52 | 2025 | Trintellix |
| Boston Scientific Corporation | $14.07 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.